Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  CNS Spectrums

• Publication date

  2016-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1017/S1092852916000729PMID 28044942
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study

  2016cited by this paper
• Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.

  2016cited by this paper
• ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes

  2016cited by this paper
• Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

  2016cited by this paper
• Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.

  2016cited by this paper
• Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

  2016cited by this paper
• Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil

  2016cited by this paper
• Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial.

  2016cited by this paper
• Schizophrenia relapse, patient considerations, and potential role of lurasidone

  2016cited by this paper
• ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.

  2016cited by this paper
• Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.

  2016cited by this paper
• Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.

  2016cited by this paper
• Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study

  2016cited by this paper
• Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study

  2016cited by this paper
• The ABC's of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15‐min challenge to sort these agents out

  2015cited by this paper
• Cognitive impairment in schizophrenia: the great unmet need

  2015cited by this paper
• Lack of tolerable treatment options for patients with schizophrenia

  2015cited by this paper
• Population pharmacokinetic modeling and simulation to guide dose selection for RBP‐7000, a new sustained‐release formulation of risperidone

  2015cited by this paper
• A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.

  2015cited by this paper
• The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?

  2015cited by this paper
• Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.

  2015cited by this paper
• A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.

  2015cited by this paper
• Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial

  2015cited by this paper
• Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

  2015cited by this paper
• Cognitive Impairment in Schizophrenia : The Great Unmet Need

  2015cited by this paper
• NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study

  2015cited by this paper
• Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.

  2015cited by this paper
• Valbenazine granted breakthrough drug status for treating tardive dyskinesia

  2015cited by this paper
• Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.

  2015cited by this paper
• Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.

  2015cited by this paper
• Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.

  2014cited by this paper
• Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study

  2014cited by this paper
• Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

  2014cited by this paper
• An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.

  2014cited by this paper
• Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States

  2014cited by this paper
• Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment

  2014cited by this paper
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

  2013cited by this paper
• A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone

  2013cited by this paper
• Kinetic deuterium isotope effects in cytochrome P450 oxidation reactions.

  2013cited by this paper
• Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse

  2013cited by this paper
• Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.

  2012cited by this paper
• Tetrabenazine for the Treatment of Tardive Dyskinesia

  2011cited by this paper
• Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.

  2010cited by this paper
• Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

  2010cited by this paper
• Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

  2009cited by this paper
• Tardive dyskinesia circa 2006.

  2006cited by this paper
• Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 1: Pathophysiology and Mechanisms of Induction

  2005cited by this paper
• Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 2: Incidence and Management Strategies in Patients with Schizophrenia

  2005cited by this paper

• Application of the quality by design (QbD) approach to the development and validation of analytical methods for the quantification of Lumateperone Tosylate as the bulk drug and capsule dosage form by HPLC

  2025cites this paper
• Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system

  2024cites this paper
• Promising Advances in Schizophrenia Treatment

  2024cites this paper
• Exploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic

  2024cites this paper
• Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine

  2023cites this paper
• Binge eating disorder

  2022cites this paper
• Efficacy of a Group Psychoeducation Treatment in Binge Eating Disorder: An Open-Label Study

  2022cites this paper
• The role of lumateperone in the treatment of schizophrenia

  2021cites this paper
• Evidence On The New Drug Lumateperone (Iti-007) For Psychiatric And Neurological Disorders.

  2020cites this paper
• The Main Gaps for Randomized-controlled Trials in Psychiatry: A Bibliometric Study

  2020cites this paper
• Lumateperone: New Drug or Same Old Drug With a New Dress?

  2020cites this paper
• An evaluation of lumateperone tosylate for the treatment of schizophrenia

  2019cites this paper
• Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

  2018cites this paper
• Valbenazine as the first and only approved treatment for adults with tardive dyskinesia

  2018cites this paper
• “Impact of drug‐reimbursement policies on prescribing: A case‐study of a newly marketed long‐acting injectable antipsychotic among relapsed schizophrenia patients”

  2018cites this paper
• Investigational dopamine antagonists for the treatment of schizophrenia

  2017cites this paper
• Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients

  2017cites this paper
• A molecular pathway analysis stresses the role of inflammation and oxidative stress towards cognition in schizophrenia

  2017cites this paper